{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:22Z","timestamp":1788355342755,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,27]]},"DOI":"10.1097\/tp.0b013e318257ad41","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T04:54:09Z","timestamp":1338526449000},"page":"1179-1188","source":"Crossref","is-referenced-by-count":97,"title":["Alemtuzumab Induction Therapy in Kidney Transplantation"],"prefix":"10.1097","volume":"93","author":[{"given":"Robert D.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":". The Campath-1 antigen (CDw52).","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antigens"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14712598.1.6.1059","article-title":"Alemtuzumab: a novel monoclonal antibody.","volume":"1","author":"Ferrajoli","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1586\/ern.10.135","article-title":"Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.","volume":"10","author":"Fox","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12185-011-0802-2","article-title":"Alemtuzumab for the prevention and treatment of graft-versus-host disease.","volume":"93","author":"Kanda","year":"2011","journal-title":"Int J Hematol"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1432-2277.2006.00343.x","article-title":"The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.","volume":"19","author":"Magliocca","year":"2006","journal-title":"Transpl Int"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00007890-199911270-00032","article-title":". Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.","volume":"68","author":"Calne","year":"1999","journal-title":"Transplantation"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0140-6736(05)77739-4","article-title":". Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.","volume":"351","author":"Calne","year":"1998","journal-title":"Lancet"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2005.00822.x","article-title":". Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantationefficacy and safety at five years.","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): a systematic review in organ transplantation.","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/TP.0b013e31822ca7ca","article-title":". Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapyan open label, randomized trial.","volume":"92","author":"Chan","year":"2011","journal-title":"Transplantation"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":". A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transplant"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.transproceed.2010.08.045","article-title":". Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation.","volume":"42","author":"Ciancio","year":"2010","journal-title":"Transplant Proc"},{"key":"R13-1-20210129","first-page":"41","article-title":". A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.","volume":"22","author":"Farney","year":"2008","journal-title":"Clin Transplant"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/TP.0b013e3181b4acfb","article-title":". A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.","volume":"88","author":"Farney","year":"2009","journal-title":"Transplantation"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":". Alemtuzumab induction in renal transplantation.","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R16-1-20210129","first-page":"664","article-title":". Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.","volume":"124","author":"Lu","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":". Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":". Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":". Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation.","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(11)70020-5","article-title":". Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.","volume":"10","author":"Coles","year":"2011","journal-title":"Lancet Neurol"},{"key":"R23-1-20210129","first-page":"1692","article-title":". Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.","volume":"122","author":"Shou","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.tp.0000281942.97406.89","article-title":". Alemtuzumab induction in deceased donor kidney transplantation.","volume":"84","author":"Huang","year":"2007","journal-title":"Transplantation"},{"key":"R25-1-20210129","first-page":"649","article-title":"Current trend of induction and maintenance treatment in positive panel-reactive antibody patients: a report on OPTNUNOS Kidney Transplant Registry data.","volume":"124","author":"Cai","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/01.tp.0000250756.66348.9a","article-title":". Risk factors for development of new-onset diabetes mellitus after kidney transplantation.","volume":"82","author":"Shah","year":"2006","journal-title":"Transplantation"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000189713.14993.db","article-title":". Campath-1H induction and the incidence of infectious complications in adult renal transplantation.","volume":"81","author":"Malek","year":"2006","journal-title":"Transplantation"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.transproceed.2005.01.054","article-title":". Fungal infections in transplant recipients receiving alemtuzumab.","volume":"37","author":"Nath","year":"2005","journal-title":"Transplant Proc"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":". Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":". Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a Collaborative Transplant Study report.","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.10733","article-title":". Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.","volume":"92","author":"Elimelakh","year":"2007","journal-title":"Haematologica"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","article-title":". Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab.","volume":"6","author":"Kirk","year":"2006","journal-title":"Am J Transplant"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":". Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":". Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":". The Banff 97 working classification of renal allograft pathology.","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int"},{"key":"R38-1-20210129","first-page":"1","article-title":"Carroll D, et al..","volume":"17","author":"Jadad","year":"1996","journal-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007890-201206270-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T21:46:58Z","timestamp":1618264018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201206270-00001"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318257ad41","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,27]]}}}